Novartis has replaced both the chief scientist and R&D head of AveXis and announced the appointment of a veteran Novartis executive to both roles at the biotech developer of the gene therapy Zolgensma. Neither Brian Kaspar nor his brother Allan Kaspar have been involved in operations at Avexis since early May, when Novartis confirmed internally the manipulation of preclinical data used to support the approval of Zolgensma. Both were placed on administrative leave and are now no longer with the company. In their place, Page Bouchard, most recently head of preclinical safety at Novartis’ research institute, assumed the positions of senior vice president of research and chief scientific officer at AveXis. Learn More